Live
FierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25BFierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BThermo FisherGlobal Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation - PR NewswireAgilentAgilent’s Expanding Role in Advanced Therapeutics - Contract PharmaBioWorldAI opens the way to systematic risk assessment of zoonotic potential of virusesBioWorldSingularity Pharma discloses new mitragynine analoguesBioWorldJiangsu Vcare Pharmatech identifies new IL-17A inhibitorsBioWorldRuijin Hospital and Shanghai Jiao Tong University discover GSPT1 degradation inducersAgilentAgilent Technologies (A) Launches Key Cancer Diagnostic Tool - GuruFocusFierceBiotechNovartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
eLife Nov 28, 2025

The <i>Shigella flexneri</i> effector IpaH1.4 facilitates RNF213 degradation and protects cytosolic bacteria against interferon-induced ubiquitylation

The Shigella flexneri effector IpaH1.4 facilitates RNF213 degradation and protects cytosolic bacteria against interferon-induced ubiquitylation

Original
Body unavailable. Use the original source.